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retroperitoneal ﬁbrosis1. Introduction
Retroperitoneal ﬁbrosis (RPF) is a rare disease characterized by
the proliferation of ﬁbroinﬂammatory tissue in the retro-
peritoneum that entraps the ureters, the abdominal aorta, the
inferior vena cava (IVC), and the iliac vessels. It may have an idio-
pathic form or a secondary form; the idiopathic form accounts for
more than 50% of cases. Because of the nonspeciﬁc symptoms and
signs of this disease and the lack of sensitive and speciﬁc laboratory
tests, imaging studies have played an important role in the diag-
nosis of RPF. As a result, multidetector computed tomography (CT)
and magnetic resonance imaging (MRI) have become the most
useful tools in the diagnosis of RPF.
2. Case report
A 75-year-old male reported that he experienced bilateral
ﬂank pain 1 month ago. The frequency and the intensity of
bilateral ﬂank pain increased gradually. He visited several hos-
pitals and was treated with analgesics, but the treatment result
was poor. Poor appetite, abdominal fullness, constipation, and a
body weight loss of 5 kg were also noted. He came to our
emergency department because a severe night ﬂank pain was
noted in the past week. Abdominal sonography was performed,* Department of Radiology, Taipei Veterans General Hospital, No. 201, Sec. 2,
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This was followed by an abdominal CT, which showed extensive
periaortic soft tissue density from the infrarenal level extending
downward to the bilateral common iliac vessels with encasement
of the upper third of bilateral ureters causing bilateral hydro-
nephrosis and bilateral proximal hydroureter (Fig. 1); the RPF
was impressed. He was subsequently admitted to our ward for
further evaluation and management. After admission, a physical
examination revealed knocking pain over the bilateral costo-
vertebral angles, which was more severe on the right side. Lab-
oratory examinations revealed a slightly impaired renal function
(blood urea nitrogen ¼ 32 mg/dL, serum creatinine ¼ 2.89 mg/
dL) and urinary tract infection (white blood cell ¼ 21e35/high
power ﬁeld in urine). Next, a right percutaneous nephrostomy
was performed, followed by a CT-guided core biopsy of the ret-
roperitoneum (Fig. 2). The pathological result showed ﬁbrous
tissue without malignant cells. Then, a bilateral double-J ureteral
stent was performed. Tamoxifen was also given. The patient was
then discharged, and an outpatient department follow-up was
recommended. Another abdominal CT was performed 3 months
later, which showed a decreased amount of retroperitoneal
periaortic soft tissue density (Fig. 3).
3. Discussion
RPF is a rare disease characterized by the proliferation of
ﬁbroinﬂammatory tissue in the retroperitoneum that entraps the
ureters, the abdominal aorta, the IVC, and the iliac vessels.1,2 It
may have an idiopathic form, which accounts for more than 50% of
cases, or a secondary form, which may result from certain drugs
(derivatives of ergot alkaloids), neoplasms, infections, radiation
therapy, major trauma, major abdominal surgery and retroperi-
toneal hemorrhage, or urine leakage1e3 It can occur at any age, but
the prevalence occurs at the age of 40e60 years.3,4 The initial
symptoms and signs of RPF are often nonspeciﬁc, such as body
weight loss, malaise, anorexia, poorly localized pain over the ﬂank,
lower back, or abdomen, and low-grade fever.5e9 As the disease
progresses, obstructive uropathy and subsequent renal failure,
lower extremity edema, and claudication develop.1,5,7e10 Labora-
tory ﬁndings reveals a high erythrocyte sedimentation rate and
C-reactive protein level, and anemia.5e8,10,11 Because of the
nonspeciﬁc symptoms and signs of this disease and the lack ofan LLC. Open access under CC BY-NC-ND license.
Fig. 1. Computed tomography (CT) of retroperitoneal ﬁbrosis. (A) Noncontrast axial and (B) noncontrast coronal CT of the abdomen revealed a well-deﬁned but irregular retro-
peritoneal para-aortic soft tissue mass extending from the level of the renal vessels to the iliac vessels. Calciﬁed plaque of abdominal aorta is noted.
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an important role in the diagnosis of RPF. Intravenous urography
and retrograde pyelography usually reveal the medial deviation of
bilateral ureters at the level of the lumbosacral junction, and
bilateral hydronephrosis and bilateral proximal hydroureter
(maiden waist sign).3 Multidetector CT and MRI have become the
most useful tools in the diagnosis of RPF. CT usually reveals a well-
deﬁned but irregular para-aortic soft tissue mass extending from
the level of the renal vessels to the iliac vessels that often entraps
bilateral ureters, IVC, and abdominal aorta. The degree of contrast
enhancement depends on the stage of the disease.2,12e16 Obvious
contrast enhancement is noted in the early stage of the disease,
but little or absent contrast enhancement is noted in the late or
inactive stage.17,18 Bilateral hydronephrosis and bilateral proximal
hydroureter are also noted. MRI usually reveals a low signal in-
tensity in the para-aortic soft tissue mass on T1-weighted images;
moreover, it shows high signal intensity on T2-weighted images
and obvious contrast enhancement on contrast enhancedFig. 2. Computed tomography-guided core biopsy of retroperitoneal para-aortic soft
tissue mass is seen. Arrow: biopsy needle; arrowhead: catheter of right percutaneous
nephrostomy.T1-weighted images in the early stage, but low T2 signal intensity
and little or absent contrast enhancement in the late inactive
stage.2,17,19e25 CT-guided core biopsy of the para-aortic mass is
useful for differentiating between the benign form and the ma-
lignant form of RPF. Prompt diagnosis and prompt treatment of
most benign forms of RPT usually lead to a good prognosis. Cor-
ticosteroids are considered the ﬁrst line of treatment for patients
with idiopathic RPF.11,26 Tamoxifen or other immunosuppressive
drugs, either alone or in combination with corticosteroids, can be
used as steroid-sparing agents or in steroid-refractory cases.27
Drainage of the upper urinary tract by temporary percutaneous
nephrostomy or ureteral stents is necessary.1,27 Surgery is reserved
for refractory cases. The standard surgical methods include open
or laparoscopic ureterolysis and intraperitonealization of the
ureter, and ureteral transposition with omental wrapping of the
involved ureter.1,22,25,28 Follow-up CT usually reveals a change in
the size of the retroperitoneal para-aortic soft tissue mass in-
dicates treatment effect.Fig. 3. Noncontrast axial computed tomography of the abdomen revealed decrease in
the size of retroperitoneal para-aortic soft tissue mass. Bilateral ureteral stents are
noted (arrows). Calciﬁed plaque of abdominal aorta is also noted.
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